Following concerns that interferon alpha formulations were about to be withdrawn from the market, Roche has said that at least one of the interferon-alpha drugs will continue to be available to the market on a long term basis. Thanks to Professor Christos Zouboulis and Colleagues from the German Registry of Adamantiades-Behçet Disease for obtaining this reassurance.